Memory Disorders Clinical Trials

Featured Study

The main goals of the Clarity AD study are to assess the safety and efficacy of the BAN2401 investigational drug for early Alzheimer’s disease. This Phase III, multicenter, randomized, double-blind, placebo-controlled study will take place over the course of 24 months and consist of three phases: Screening, Treatment, and Follow Up. The study will enroll a total of 1566 participants between ages of 50 to 90 with a recent history of memory decline with gradual progression over the last year. Participants who complete 18 months of core treatment may be eligible to receive open-label treatment (where all participants will receive the investigational drug) for up to 2 years. To learn more about this clinical trial opportunity enrolling at the Stanford Neuroscience Health Center, contact the Study Coordinator at (650) 709-9041 or viktoriya.bourakova@stanford.edu.

Learn more

 

Stanford Memory Disorders Clinical Trials

Active, recruiting:

Sponsor: Eisai and Biogen (Clarity AD) 
Intervention: BAN2401 (Monoclonal antibody binding to amyloid)
Indication: MCI
Clinicaltrials.gov identifier: NCT03887455
PI: Sharon Sha, MD
Contact: Viktoriya Bourakova, viktoriya.bourakova@stanford.edu
Inclusion criteria:
·       MMSE score >=22 at Screening
·       CDR (global) 0.5 or 1
·       Age 50-90
·       Stable AD meds for > 3 months

Active, not recruiting:

Sponsor: Genentech (Lauriet Study)
Intervention: RO7105705 (Monoclonal antibody binding to tau)
Indication: Moderate AD
Clinicaltrials.gov identifier: NCT03828747
PI: Sharon Sha, MD
Contact: Jenn Gaudioso, jenn.gaudioso@stanford.edu

Sponsor: Biogen (Tango Study)
Intervention: BIIB092 (Monoclonal antibody binding to tau)
Indication: MCI/Mild AD
Clinicaltrials.gov identifier: NCT03352557
PI: Sharon Sha, MD
Contact: Viktoriya Bourakova, viktoriya.bourakova@stanford.edu

Sponsor: Genentech (Tauriel Study)
Intervention: RO7105705 (Monoclonal antibody binding to tau)
Indication: MCI/Mild AD
Clinicaltrials.gov identifier: NCT03289143
PI: Sharon Sha, MD
Contact: Jenn Gaudioso, jenn.gaudioso@stanford.edu

Sponsor: Alzheimer's Disease Cooperative Study (PeaceAD Study)
Intervention: Prazosin
Indication: Probable or possible AD and disruptive agitation
Clinicaltrials.gov identifier: NCT03710642
PI: Victor Henderson, MD and Sharon Sha, MD
Contact: Amanda Ng, amandang@stanford.edu

Sponsor: Cortexyme (Gain Study) 
Intervention: COR388 (Gingipain inhibitor) 
Indication: Mild to Moderate AD
Clinicaltrials.gov identifier: NCT03823404
PI: Sharon Sha, MD
Contact: Amanda Ng, amandang@stanford.edu

Completing, not recruiting:

Sponsor: Novartis (Generations II Study)
Intervention: CNP520 (Active BACE-1 Inhibitor)
Target Population: Cognitively Unimpaired APOE4 Homozygotes or Amyloid Positive Heterozygotes
Clinicaltrials.gov identifier: NCT03131453
PI: Sharon Sha, MD
Contact: Amanda Ng, amandang@stanford.edu

Sponsor: Novartis (Generations I Study)
Intervention: CAD106 (Induces Active Antibody without activating Aβ-reactive T cells) and CNP520 (BACE-1 Inhibitor)
Target Population: Cognitively Unimpaired APOE4 Homozygotes
Clinicaltrials.gov identifier: NCT02565511
PI: Sharon Sha, MD
Contact: Amanda Ng, amandang@stanford.edu

Upcoming: (Recruiting by invitation only: participants who were previously enrolled in aducanumab trials) 

Sponsor: Biogen (Embark Study)
Intervention: Aducanumab (Monoclonal antibody binding to amyloid)
Indication: MCI/Mild AD
Clinicaltrials.gov identifier: NCT04241068
PI: Sharon Sha, MD
Contact: Jenn Gaudioso, jenn.gaudioso@stanford.edu

Clinical trials contacts

memoryresearch@stanford.edu
(650) 724-8736

Sharon Sha, MD, MS
Clinical Assistant Professor, Neurology & Neurological Sciences
Director, Memory Disorders Clinical Trials
ssha1@stanford.edu
(650) 723-5072